CA2697055A1 - Methods and compositions for post-transcriptional gene silencing - Google Patents

Methods and compositions for post-transcriptional gene silencing Download PDF

Info

Publication number
CA2697055A1
CA2697055A1 CA2697055A CA2697055A CA2697055A1 CA 2697055 A1 CA2697055 A1 CA 2697055A1 CA 2697055 A CA2697055 A CA 2697055A CA 2697055 A CA2697055 A CA 2697055A CA 2697055 A1 CA2697055 A1 CA 2697055A1
Authority
CA
Canada
Prior art keywords
dsrna
strand
vector
expression
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2697055A
Other languages
English (en)
French (fr)
Inventor
Alexzander Asea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor Scott & White Health
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2697055A1 publication Critical patent/CA2697055A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2697055A 2007-08-21 2008-08-21 Methods and compositions for post-transcriptional gene silencing Abandoned CA2697055A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95709707P 2007-08-21 2007-08-21
US60/957,097 2007-08-21
PCT/US2008/073872 WO2009026445A2 (en) 2007-08-21 2008-08-21 Methods and compositions for post-transcriptional gene silencing

Publications (1)

Publication Number Publication Date
CA2697055A1 true CA2697055A1 (en) 2009-02-26

Family

ID=40378991

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2697055A Abandoned CA2697055A1 (en) 2007-08-21 2008-08-21 Methods and compositions for post-transcriptional gene silencing

Country Status (6)

Country Link
US (1) US20100186102A1 (enExample)
EP (1) EP2185702A4 (enExample)
JP (1) JP2010536380A (enExample)
AU (1) AU2008288846A1 (enExample)
CA (1) CA2697055A1 (enExample)
WO (1) WO2009026445A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339050B (es) * 2009-12-18 2016-05-09 Novartis Ag Composiciones organicas para tratar las enfermedades relacionadas con hsf1.
US20120308642A1 (en) * 2011-05-27 2012-12-06 Xavier University Of Louisiana Inhibiting hepatitis c viral replication with sirna combinations
US20140351961A1 (en) * 2011-08-31 2014-11-27 Alexzander A. Asea Compositions and methods for treatment of metastatic cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080023768A (ko) * 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna

Also Published As

Publication number Publication date
AU2008288846A1 (en) 2009-02-26
EP2185702A4 (en) 2011-05-04
WO2009026445A3 (en) 2009-05-07
EP2185702A2 (en) 2010-05-19
JP2010536380A (ja) 2010-12-02
WO2009026445A2 (en) 2009-02-26
US20100186102A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
Rumpold et al. RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines
US8808983B2 (en) shRNA molecules and methods of use thereof
WO2011014388A1 (en) Adipose-derived stromal cells (asc) as delivery tool for treatment of cancer
US20100086526A1 (en) Nucleic acid constructs and methods for specific silencing of h19
JP2012510820A (ja) 血管新生促進ｖｅｇｆイソ型を選択的に抑制する組成物および方法
JP2011507554A (ja) 遺伝子発現を増加させるための方法および組成物
WO2016030501A1 (en) Synthetic alu-retrotransposon vectors for gene therapy
WO2012091496A2 (en) siRNA FOR INHIBITION OF Hif1α EXPRESSION AND ANTICANCER COMPOSITION CONTAINING THE SAME
Wan et al. Crab-shaped DNA tetrahedral nanomachine for silencing undruggable mRNA targets in prostate cancer
US20100186102A1 (en) Methods and compositions for post-transcriptional gene silencing
CA2551100A1 (en) Compositions and methods for combined therapy of disease
US20140351961A1 (en) Compositions and methods for treatment of metastatic cancer
Pan et al. Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro
EP4286518A1 (en) Cancer-specific trans-splicing ribozyme expressing immune checkpoint inhibitor, and use thereor
Yin et al. Asymmetric siRNA targeting the bcl-2 gene inhibits the proliferation of cancer cells in vitro and in vivo
US20100098663A2 (en) Methods of Inhibiting Tumor Cell Proliferation with FoxM1 siRNA
CN102051362B (zh) 靶向hpip基因的干扰性rna、含有该干扰性rna的药物组合物及其应用
EP2258393A1 (en) Abc transporter protein expression inhibitor
KR102950211B1 (ko) 항종양능을 갖는 grp78 발현 억제용 핵산 분자
US8188252B2 (en) Rad51 derived cancer cell specific promoters for targeted anti-cancer therapy
EP1861496A2 (en) Inhibition of spag9 expression with sirnas
KR20060096872A (ko) 뇌하수체 종양-형질전환 유전자 1 단백질의 합성을 차단할수 있는 작은 간섭 ｒｎａ 및 이를 발현하는 벡터를 이용한 암의 유전자 치료

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140821